Log In
Print this Print this

Eprex, Procrit, epoetin alfa

Also known as: EPO

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionRecombinant erythropoietin (EPO) alfa
Molecular Target Erythropoietin (EPO) receptor
Mechanism of ActionErythropoietin (EPO) receptor agonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationAnemia
Indication DetailsTreat anemia; Treat anemia associated with chronic renal failure (CRF); Treat anemia in cancer patients; Treat anemia in cancer patients receiving chemotherapy; Treat anemia in chronic heart failure (CHF) patients; Treat anemia in critically ill patients; Treat anemia in patients with cervical cancer; Treat anemia in patients with chronic kidney disease (CKD); Treat anemia in premature infants; Treat anemia related to azidothymidine (AZT) treatment in HIV patients; Treat anemic patients with lower-risk myelodysplastic syndromes (MDS); Treat chemotherapy-induced anemia (CIA); Treat chemotherapy-induced anemia (CIA) in patients with cancer; Treat chemotherapy-related anemia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today